STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARCT
  4. [8-K] Arcturus Therapeutics Holdings Inc. Reports Material Event

Arcturus Therapeutics (Nasdaq: ARCT) Q2 2026 revenue falls as losses deepen

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. reported Q2 2026 results with total revenue of $3.0 million, down from $28.3 million a year earlier, mainly reflecting reduced collaboration revenue as it moves toward terminating the CSL Seqirus agreement and regaining rights to KOSTAIVE and its infectious disease vaccine portfolio.

The company recorded a net loss of $23.8 million, or $0.84 per share, compared with a $9.2 million loss and $0.34 per share in Q2 2025. Cash and cash equivalents were $191.5 million as of June 30, 2026, versus $230.9 million at December 31, 2025, and management cites a cash runway of over two and a half years through year end 2028.

R&D expenses declined to $17.5 million from $29.6 million as spending was focused on highest-priority programs. ARCT-032 cystic fibrosis Phase 2 enrollment remains on schedule with a Phase 3 proceed decision expected in Q4 2026, while ARCT-810 Phase 2 enrollment and dosing have completed, with data and a regulatory plan to be communicated in Q3 2026.

Positive

  • The CSL Seqirus termination and settlement provides $12 million in cash plus $16 million in released liabilities and R&D credits, while returning global rights to KOSTAIVE and the broader infectious disease vaccine portfolio.
  • Management reports cash and cash equivalents of $191.5 million and describes a cash runway of over two and a half years through year end 2028, supporting planned clinical and regulatory milestones for the rare disease pipeline.

Negative

  • Total revenue for Q2 2026 was $3.0 million, sharply lower than $28.3 million in the prior-year quarter, primarily due to reduced revenue recognized under the CSL Seqirus collaboration.
  • Q2 2026 net loss widened to $23.8 million, or $0.84 per share, from a $9.2 million loss, or $0.34 per share, a year earlier, with first-half net loss rising to $50.7 million from $23.3 million.

Filing Explained

Arcturus reports that it has regained global rights to KOSTAIVE and its infectious-disease portfolio; the associated settlement provides $12 million in cash plus $16 million in released liabilities and research-and-development credits.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Cash and cash equivalents $191.5 million As of June 30, 2026; down from $230.9 million at December 31, 2025
Total revenue Q2 2026 $3.0 million Three months ended June 30, 2026; compared with $28.3 million in Q2 2025
Total revenue H1 2026 $5.0 million Six months ended June 30, 2026; compared with $57.7 million in the 2025 period
Research and development expense Q2 2026 $17.5 million Three months ended June 30, 2026; down from $29.6 million in Q2 2025
General and administrative expense Q2 2026 $11.0 million Three months ended June 30, 2026; slightly above $10.3 million in Q2 2025
Net loss Q2 2026 $23.8 million Quarter ended June 30, 2026; compared with $9.2 million net loss in Q2 2025
Net loss per share Q2 2026 $0.84 Basic and diluted net loss per share for the quarter ended June 30, 2026; versus $0.34 a year earlier
Cash runway Over two and a half years Management cites runway through year end 2028 based on current cash position and plans
self-amplifying messenger RNA (sa-mRNA) medical
"the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world"
LUNAR® lipid-mediated delivery technical
"with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA"
ornithine transcarbamylase (OTC) deficiency medical
"ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed"
Ornithine transcarbamylase (OTC) deficiency is a genetic disorder in which the liver lacks a key enzyme that helps remove ammonia produced when the body breaks down protein; without it, ammonia can build up to toxic levels and cause brain damage or death. For investors, OTC deficiency matters because it creates a defined patient population and clear medical need that drives demand for diagnostics, therapies, and regulatory attention—similar to a clogged waste pipe creating a strong market for repair solutions.
deferred revenue financial
"Deferred revenue | | | 6,276 | | | | 8,246"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
operating lease right-of-use assets financial
"Operating lease right-of-use assets, net | | | 19,758"
An operating lease right-of-use (ROU) asset is an accounting entry that shows the value of a leased item you have the legal right to use—like a building, vehicle, or equipment—recorded on a company’s balance sheet along with the corresponding lease obligation. Investors care because it adds to reported assets and liabilities, changing measures like leverage and return on assets much like bringing a long-term rental onto the company’s financial snapshot, which can affect credit terms and valuation.
Total revenue Q2 2026 $3.0 million Decrease from $28.3 million in Q2 2025
Net loss Q2 2026 $23.8 million Wider than $9.2 million in Q2 2025
Net loss per share Q2 2026 $0.84 Wider than $0.34 in Q2 2025
Cash and cash equivalents $191.5 million Down from $230.9 million at December 31, 2025
Guidance

Management states a cash runway of over two and a half years through year end 2028 and outlines Q3 2026 and Q4 2026 decision points for ARCT-810 and ARCT-032, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

How much revenue did Arcturus Therapeutics (ARCT) report for Q2 2026?
Arcturus reported Q2 2026 revenue of $3.0 million, compared with $28.3 million in Q2 2025. The decline mainly reflects lower collaboration revenue as the company progresses toward terminating the CSL Seqirus agreement and regaining rights to KOSTAIVE and its infectious disease vaccine portfolio.

What was Arcturus Therapeutics' (ARCT) net loss and EPS in Q2 2026?
Arcturus posted a net loss of $23.8 million, or $0.84 per share, in Q2 2026. This compares with a net loss of $9.2 million, or $0.34 per share, in the prior-year quarter, reflecting lower revenue despite reduced research and development spending.

What is Arcturus Therapeutics' (ARCT) cash position and runway after Q2 2026?
As of June 30, 2026, Arcturus held $191.5 million in cash and cash equivalents, down from $230.9 million at year-end 2025. Management states this supports a cash runway of over two and a half years through year end 2028, funding key rare disease programs.

What update did Arcturus Therapeutics (ARCT) provide on its ARCT-032 cystic fibrosis program?
The ARCT-032 cystic fibrosis Phase 2 study continues with enrollment on schedule across sites in the United States, Israel, and Turkey. The company expects to make a decision to proceed into a Phase 3 study in Q4 2026, subject to Phase 2 outcomes and planning.

What is the status of Arcturus Therapeutics' (ARCT) ARCT-810 OTC deficiency study?
For ARCT-810 targeting ornithine transcarbamylase deficiency, Phase 2 enrollment and dosing have been completed. Arcturus plans to communicate Phase 2 data and a regulatory plan in Q3 2026, outlining potential next steps for this rare liver disease program.

How did the CSL Seqirus termination affect Arcturus Therapeutics (ARCT)?
The CSL Seqirus termination and settlement allows Arcturus to regain global rights to KOSTAIVE and its infectious disease portfolio. It also delivers $12 million in cash and $16 million in released liabilities and R&D credits, which management says strengthens its financial position.

When is the Arcturus Therapeutics (ARCT) Q2 2026 earnings call scheduled?
Arcturus scheduled its investor conference call for Thursday, August 6, 2026, at 4:30 p.m. ET. Management plans to discuss second quarter 2026 financial results and progress across the company’s cystic fibrosis, OTC deficiency, and infectious disease vaccine programs.
false 0001768224 0001768224 2026-08-06 2026-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 6, 2026

 

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38942   32-0595345
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

10285 Science Center Drive

San Diego, California 92121 

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (858) 900-2660

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

   Name of each exchange
on which registered
Common stock, par value $0.001 per share   ARCT   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

Item 2.02. Results of Operations and Financial Conditions.

 

On August 6, 2026, Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended June 30, 2026 and providing a corporate update (the “Press Release”).

 

The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission (the “SEC”), except as shall be expressly set forth by specific reference in any such filing.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report on Form 8-K and the Press Release contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this Current Report on Form 8-K and the Press Release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company’s pipeline (including ARCT-032 and ARCT-810), the likelihood that the Company will continue to advance its rare disease therapeutics portfolio including its inhaled mRNA therapy, the likelihood that the ARCT-032 (CF) Phase 2 study enrollment will remain on schedule, the timing for a decision to proceed into a Phase 3 study for ARCT-032, the communication of a data and regulatory plan for ARCT-810 and timing thereof, the likelihood that the Company will be able to increase the value of its sa-mRNA vaccine platform including likelihood that the Company will develop, commercialize or seek partnership opportunities related to KOSTAIVE and its other infectious disease vaccine programs, the ability of the Company to reach important clinical and regulatory milestones for its rare disease pipeline, the likelihood that clinical data, including interim data, will be predictive of future clinical results, its current cash position and expected cash burn and runway, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise..

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description of Exhibit
   
99.1 Press Release dated August 6, 2026
104 Cover Page to this Current Report on Form 8-K in Inline XBRL

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 6, 2026 Arcturus Therapeutics Holdings Inc.
   
  By: /s/ Joseph E. Payne
  Name: Joseph E. Payne
  Title: Chief Executive Officer

 

 

 

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

 

ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026

 

ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026

 

Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&D credits

 

Investor conference call at 4:30 p.m. ET today

 

SAN DIEGO--(BUSINESS WIRE) -- August 6, 2026 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates.

 

“We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States, Israel, and Turkey. With dosing completed of all subjects in our ARCT-810 Phase 2 OTC deficiency study, we look forward to sharing the data and regulatory plan later this quarter,” said Joseph Payne, President & CEO of Arcturus. "We are also pleased to regain strategic control of KOSTAIVE® and our infectious disease vaccine portfolio, enhancing our ability to increase the value of our validated sa-mRNA vaccine platform."

 

Recent Corporate Highlights

·ARCT-032, an inhaled mRNA therapeutic candidate for cystic fibrosis, continues to advance in an open-label Phase 2 study in people with Class I CF mutations. Cohort 4 is evaluating 10 mg daily dosing, via inhalation, over 12 weeks and monitoring safety and evidence of early clinical benefit, including pulmonary function measures such as ppFEV1 and lung clearance index (LCI), quality-of-life measures, and high-resolution computed tomography (HRCT) imaging. Enrollment is advancing as expected, with active screening and enrollment in the U.S., Israel, and Turkey. Israel and Turkey are geographies with a high prevalence of individuals with Class I/null CF mutations, supporting recruitment efforts in the ongoing study. The decision to advance ARCT-032 into Phase 3 is expected in Q4 2026, triggering significant resources and support from Thermo Fisher.
·Arcturus announced a strategic collaboration with Thermo Fisher Scientific to advance ARCT-032 for cystic fibrosis. Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services. If Phase 2 yields positive results, Arcturus expects to conduct its Phase 3 program through Thermo Fisher’s PPD™ clinical research business. Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate commercial agreement.
·ARCT-810, an mRNA therapeutic candidate for OTC deficiency, has completed enrollment of the ongoing Phase 2 study, and all enrolled subjects have completed study drug dosing. The Company continues to evaluate supplementary data to inform regulatory discussions and preparation for an End-of-Phase 2 meeting regarding the path forward across adult and pediatric development. Data and the regulatory plan for this program is expected to be communicated later this quarter.

 

 

  

 

·Arcturus and CSL Seqirus have concluded their sa-mRNA collaboration through a termination and settlement agreement following a joint review of the partnership. Under the agreement, Arcturus regained global rights to KOSTAIVE® and the broader infectious disease vaccine portfolio, including seasonal influenza, pandemic influenza, RSV, and EBV vaccine programs, subject to existing arrangements with Meiji Seika Pharma for the 2026-2027 season in Japan. The agreement also resolves the arbitration relating to a European regulatory approval milestone payment.
oUnder the agreement, CSL Seqirus will make a one-time cash payment of $12 million to Arcturus. In addition, Arcturus will be released from liabilities associated with an R&D credit with an aggregate value of approximately $16 million.
oWith strategic control of the portfolio returned to Arcturus, the Company intends to evaluate opportunities to maximize its future value, including development, commercialization, and partnering opportunities related to KOSTAIVE®, and the broader infectious disease vaccine portfolio.

 

“We remain focused on disciplined execution and capital allocation as we advance our rare disease programs,” said Dennis Mulroy, Chief Financial Officer of Arcturus. “The CSL Seqirus termination and settlement agreement strengthens our financial position, and the Thermo Fisher collaboration supports execution of late-stage development for our CF program. We continue to maintain a strong balance sheet and cash runway of over two and a half years through year end 2028, allowing our company to reach important clinical and regulatory milestones for its rare disease pipeline.”

 

Financial Results for the three months ended June 30, 2026

 

Cash Position and Balance Sheet

Cash and cash equivalents were $191.5 million as of June 30, 2026, and $230.9 million on December 31, 2025, for a decrease of $39.4 million. The decrease was primarily driven by cash used related to ongoing clinical development activities, including the continued advancement of the Company's ARCT-032 cystic fibrosis and ARCT-810 OTC deficiency programs.

 

Revenue in conjunction with strategic alliances and collaborations

Revenue was $3.0 million and $5.0 million for the three and six months ended June 30, 2026, respectively, compared with $28.3 million and $57.7 million in the comparable periods last year. The decreases in revenue were primarily attributable to lower revenue recognized under the CSL Seqirus collaboration as the Company progressed toward the termination of the agreement and regaining rights to KOSTAIVE® and its broader infectious disease vaccine portfolio.

 

Research and development expenses

Research and development expenses were $17.5 million and $39.0 million for the three and six months ended June 30, 2026, respectively, compared with $29.6 million and $64.5 million for the corresponding periods in 2025. The decreases were primarily driven by lower research and development spending including reduced salaries, wages, benefits and facilities costs as the Company continued to advance its highest-priority programs while maintaining a disciplined approach to capital allocation.

 

 

  

 

General and administrative expenses

General and administrative expenses were $11.0 million and $20.5 million for the three and six months ended June 30, 2026, respectively, compared with $10.3 million and $21.7 million in the comparable periods last year. Overall, general and administrative expenses remained relatively consistent across periods with a slight quarter-to-date increase due to legal fees partly offset by reduced salaries, wages, benefits and facilities costs.

 

Net loss

Net loss was $23.8 million and $50.7 million for the three and six months ended June 30, 2026, or a net loss per share of $0.84 and $1.79, compared to a net loss of $9.2 million and $23.3 million for the three and six months ended June 30, 2025, or a net loss per share of $0.34 and $0.86.

 

Earnings Call: Thursday, August 6, 2026 @ 4:30 p.m. ET

·Domestic: 1-800-347-6865
·International: 1-203-518-9757
·Conference ID: ARCTURUS
·Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1769554&tp_key=96c7f551a6

  

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus' strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.

 

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company’s pipeline (including ARCT-032 and ARCT-810), the likelihood that the Company will continue to advance its rare disease therapeutics portfolio including its inhaled mRNA therapy, the likelihood that the ARCT-032 (CF) Phase 2 study enrollment will remain on schedule, the timing for a decision to proceed into a Phase 3 study for ARCT-032, the communication of a data and regulatory plan for ARCT-810 and timing thereof, the likelihood that the Company will be able to increase the value of its sa-mRNA vaccine platform including likelihood that the Company will develop, commercialize or seek partnership opportunities related to KOSTAIVE and its other infectious disease vaccine programs, the ability of the Company to reach important clinical and regulatory milestones for its rare disease pipeline, the likelihood that clinical data, including interim data, will be predictive of future clinical results, its current cash position and expected cash burn and runway, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

 

 

  

 

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   June 30,
2026		  December 31,
2025
(in thousands, except par value information)   (unaudited)      
Assets          
Current assets:          
Cash and cash equivalents  $191,483   $230,909 
Accounts receivable   1,813    5,564 
Prepaid expenses and other current assets   3,865    4,973 
Total current assets   197,161    241,446 
Property and equipment, net   5,363    6,736 
Operating lease right-of-use assets, net   19,758    21,081 
Non-current restricted cash   2,028    1,885 
Total assets  $224,310   $271,148 
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $4,414   $4,235 
Accrued liabilities   22,846    23,898 
Deferred revenue   6,276    8,246 
Total current liabilities   33,536    36,379 
Operating lease liabilities, net of current portion   18,966    20,784 
Total liabilities   52,502    57,163 
Stockholders’ equity          
Common stock, $0.001 par value; 60,000 shares authorized; issued and
outstanding shares were 28,423 at June 30, 2026 and 28,414 at December 31, 2025		   28    28 
Additional paid-in capital   737,119    728,547 
Accumulated deficit   (565,339)   (514,590)
Total stockholders’ equity   171,808    213,985 
Total liabilities and stockholders’ equity  $224,310   $271,148 

 

 

  

 

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

 

   Three Months Ended  Six Months Ended
   June 30,  June 30,
(in thousands, except per share data)  2026  2025  2026  2025
Revenue:            
Collaboration revenue  $880   $24,510   $1,490   $49,987 
Grant revenue   2,079    3,791    3,530    7,696 
Total revenue   2,959    28,301    5,020    57,683 
Operating expenses:                    
Research and development, net   17,515    29,579    39,042    64,471 
General and administrative   10,989    10,338    20,454    21,654 
Total operating expenses   28,504    39,917    59,496    86,125 
Loss from operations   (25,545)   (11,616)   (54,476)   (28,442)
Finance income, net   1,819    2,567    3,751    5,339 
Other expense   (59)   (127)   (24)   (149)
Net loss before income taxes   (23,785)   (9,176)   (50,749)   (23,252)
Provision for income taxes   —    4    —    4 
Net loss  $(23,785)  $(9,180)  $(50,749)  $(23,256)
Net loss per share, basic and diluted  $(0.84)  $(0.34)  $(1.79)  $(0.86)
Weighted-average shares outstanding, basic and diluted   28,423    27,129    28,422    27,118 
Comprehensive loss:                    
Net loss  $(23,785)  $(9,180)  $(50,749)  $(23,256)
Comprehensive loss  $(23,785)  $(9,180)  $(50,749)  $(23,256)

 

Contacts

Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents